Effects of three kinds of tea beverages on intestinal first-pass effect and liver Cyp3a, Cyp2e1 activities in mice

Abstract

Abstract: AIM: To investigate the effect of can packaged commercially available green tea, ice black tea and jasmine tea on intestinal first-pass effect and liver Cytochrome P450 (CYPs) Cyp3a, Cyp2e1 activities in mice.METHODS: SPF grade mice were randomly divided into 6 groups, green tea group, ice black tea group, jasmine tea group mice were getting freely access to green tea, ice black tea, jasmine tea respectively for 7 days. Intestinal first-pass effect was inferred through serum acetaminophen (APAP) levels. Liver/intestinal microsomes were prepared by differential centrifugation, and microsomal protein was quantified by Bradford method. Cyp3a, Cyp2e1 activities and serum APAP concentrations were assayed by spectrophotometry.RESULTS: APAP concentrations in green tea group were significantly higher than those in control group (P<0.01), while the levels were notably lower in ice black tea group than those in control group (P<0.01), the intestinal Cyp3a activities in green tea group and ice black tea group were considerably higher than those in control group (P<0.05 or P<0.01). Compared with control group, liver Cyp3a activities in all tea treated groups were greatly increased than those in control group (P<0.01). Compared with control group, liver Cyp2e1 activities in all tea treated groups were obviously reduced (P<0.01).CONCLUSION: Green tea and iced black tea seem significantly change the intestinal first-pass effect (green tea inhibit the activities of intestinal P-gp but induce intestinal Cyp3a, and ice black tea induce both intestinal P-gp and Cyp3a activities), while jasmine tea has no effect on intestinal first-pass effect. All three kinds of tea can significantly induce liver Cyp3a activities and inhibit liver Cyp2e1 activities. Therefore, intensely or frequently consuming these tea beverages during taking the medicines by which are metabolized or transported CYP3A, CYP2E1 and P-gp probably affect the drugs' clinical efficacy.

Key words: Tea beverages, Cyp3a, Cyp2e1, P-glycoprotein

CLC Number:

R965.2

LIN Mei, QI Jin-feng, WANG Yong-hui, LIU Jian-min, HAN Jian. Effects of three kinds of tea beverages on intestinal first-pass effect and liver Cyp3a, Cyp2e1 activities in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 5-12.

References

[1] Wilkinson GR. Drug metabolism and variability among patients in drug response[J]. N Engl J Med, 2005, 352(21): 2211-2221.
[2] Wijnen PA, Op den Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms[J]. Aliment Pharmacol Ther, 2007, 26(2): 211-219.
[3] 易飞, 周宏灏. 天然药对CYP3A的影响[J]. 中国临床药理学与治疗学,2008,13(3): 344-349.
[4] Porubsky PR, Meneely KM, Scott EE. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates[J]. J Biol Chem, 2008, 283(48): 33698-33707.
[5] Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol[J]. Free Radic Biol Med, 2008, 44(5): 723-738.
[6] Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein)[J]. The Oncologist, 2007, 12(8): 927-941.
[7] Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers[J]. Drug Metab Rev, 2002, 34(1/2): 47-54.
[8] Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine[J]. Eur J Pharm Sci, 2000, 12(1): 3-12.
[9] 毛晓琴, 谢海棠, 周宏灏. 多药耐药蛋白和CYP3A4介导的中草药-西药相互作用[J]. 中国临床药理学与治疗学, 2007, 12(7): 728-734.
[10]杜继煜, 白岚, 白宝璋. 茶叶的主要化学成分[J]. 农业与技术, 2003, 23(1): 53-55.
[11]Almond LM, Yang J, Jamei M, et al. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction[J]. Curr Drug Metab, 2009, 10(4): 420-432.
[12]Dasgupta A, Reyes MA, Risin SA, et al. Interaction of white and pink grapefruit juice with acetaminophen (paracetamol) in vivo in mice[J]. J Med Food, 2008, 11(4):795-798.
[13]Shihana F, Dissanayake D, Dargan P, et al. A modified low-cost colorimetric method for paracetamol (acetaminophen) measurement in plasma[J]. Clin Toxicol(Phila), 2010, 48(1): 42- 46.
[14]Letelier ME, Pimentel A, Pino P, et al. Microsomal UDP-glucuronyltransferase in rat liver: oxidative activation[J]. Basic Clin Pharmacol Toxicol, 2005, 96(6): 480-486.
[15]Bray BJ, Goodin MG, Inder RE, et al. The effect of retinol on hepatic and renal drug-metabolising enzymes[J]. Food Chem Toxicol, 2001, 39(1): 1-9.
[16]Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine[J]. Clin Invest Med,1989,12(6): 357-362.
[17]Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age[J]. Drug Metab Dispos, 2005, 33(11): 1603-1607.
[18]Marathe PH, Rodrigues AD. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models[J]. Methods Mol Biol, 2010, 596: 385-403.
[19]Del Amo EM, Heikkinen AT, Monkkonen J. In vitro-in vivo correlation in P-glycoproteinmediated transport in intestinal absorption[J]. Eur J Pharm Sci, 2009, 36(2/3): 200-211.
[20]Kim RB. Drug transporters in HIV Therapy[J]. Top HIV Med, 2003, 11(4):136-139.
[21]Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay[J]. Mol Pharm, 2009, 6(6):1631-1643.
[22]Manov I, Bashenko Y, Hirsh M, et al. Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells[J]. Basic Clin Pharmacol Toxicol, 2006, 99(3): 213-224.
[23]Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation[J]. Clin Pharmacol Ther, 2000, 67(3): 275-282.
[24]Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with PGlycoprotein[J]. Antimicrob Agents Chemother, 2002, 46(1): 160-165.
[25]Court MH, Duan SX, Von Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP glucuronosyltransferase isoforms[J]. J Pharmacol Exp Ther, 2001, 299(3): 998-1006.
[26]Burchell B. Genetic variation of human udp-glucuronosyltransferase implications in disease and drug glucuronidation[J]. Am J Pharmacogenomics, 2003, 3(1): 37-52.
[27]Reiter C, Weinshilboum R. Platelet phenol sulfotransferase activity: Correlation with sulfate conjugation of acetaminophen[J]. Clin Pharmacol Ther, 1982, 32(5): 612-621.
[28]Pacifici GM. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: A review of the literature[J]. Int J Clin Pharmacol Ther, 2004, 42(9):488-495.
[29]Dahlin DC, Miwa GT, Lu AY, et al. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen[J]. Proc Natl Acad Sci USA, 1984, 81(5):1327-1331.
[30]Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation[J]. Clin Pharmacol Ther, 2000, 67(3): 275-282.
[31]Cheng J, Ma X, Krausz KW, et al. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity[J]. Drug Metab Dispos, 2009, 37(8): 1611-1621.
[32]Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 “pie”[J]. Drug Metab Dispos,2006,34(5): 880-886.
[33]van Heeswijk RP, Cooper CL, Foster BC, et al. Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity[J]. Pharmacotherapy, 2005, 25(12):1725-1728.
[34]EI-Masry EM, Abou-Donia MB. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid[J]. Life Sci, 2003,73(8): 981-991.
[35]Ganzera M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes[J]. Life Sci, 2006, 78(8):856-861.
[36]Furumiya K, Mizutani T. Inhibition of human CYP3A4, UGT1A6, and P-glycoprotein with halogenated xanthene food dyes and prevention by superoxide dismutase[J]. J Toxicol Environ Health A, 2008, 71(19):1307-1313.
[37]Zhao R, Wang W, Zhao L, et al. Effect of volatile oil from nutmeg on liver microsomal cytochrome P450 in mice[J]. Zhongguo Zhong Yao Za Zhi, 2009, 34(4): 447-449.
[38]Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities[J]. Drug Metab Dispos, 2004, 32(6): 647-660.
[39]Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol[J]. Free Radic Biol Med, 2008, 44(5):723-738.
[40]刘滔滔, 梁宁生, 李艳, 等. 长期服用茶多酚对大鼠肝药酶活性的影响[J]. 广西医科大学学报, 2001, 18(3): 301-303.
[41]Chen X, Sun CK, Han GZ, et al. Protective effect of tea polyphenols against paracetamol-induced hepatotoxicity in mice is significantly correlated with cytochrome P450 suppression[J]. World J Gastroenterol, 2009, 15(15): 1829-1835.